Strs Ohio Cytokinetics Inc Transaction History

Strs Ohio

$26.2 Billion
Q3 2025

A detailed history of Strs Ohio transactions in Cytokinetics Inc stock. As of the latest transaction made, Strs Ohio holds 10,600 shares of CYTK stock, worth $704,264. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,600

Previous 7,600 39.47%

Holding current value

$704,264

Previous $251,000 131.87%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 30, 2025	BUY	$33.23 - $54.96 $99,689 - $164,880	3,000 Added 39.47%	10,600 $582,000
Q2 2025 Aug 04, 2025	SELL	$29.84 - $42.92 $83,552 - $120,176	-2,800 Reduced 26.92%	7,600 $251,000
Q1 2025 May 28, 2025	SELL	$40.19 - $51.12 $56,266 - $71,568	-1,400 Reduced 11.86%	10,400 $417,000
Q3 2024 Nov 01, 2024	SELL	$51.22 - $60.16 $25,610 - $30,080	-500 Reduced 4.07%	11,800 $623,000
Q2 2024 Aug 05, 2024	BUY	$47.86 - $75.05 $114,864 - $180,120	2,400 Added 24.24%	12,300 $666,000

Q1 2024 May 13, 2024	BUY	$63.75 - $108.06 $280,500 - $475,464	4,400 Added 80.0%	9,900 $694,000
Q2 2023 Jul 31, 2023	BUY	$32.62 - $40.75 $39,144 - $48,900	1,200 Added 27.91%	5,500 $179,000
Q1 2023 Aug 02, 2023	SELL	$33.36 - $45.71 $40,032 - $54,852	-1,200 Reduced 21.82%	4,300 $151,000
Q4 2022 Jan 26, 2023	SELL	$35.77 - $51.11 $160,965 - $229,995	-4,500 Reduced 51.14%	4,300 $197,000
Q3 2022 Oct 27, 2022	BUY	$38.54 - $54.52 $73,226 - $103,588	1,900 Added 27.54%	8,800 $426,000
Q2 2022 Jul 25, 2022	BUY	$33.93 - $48.92 $217,152 - $313,088	6,400 Added 1280.0%	6,900 $271,000
Q4 2021 Jan 24, 2022	BUY	$34.35 - $46.38 $17,175 - $23,190	500 New	500 $22,000

Others Institutions Holding CYTK

# of Institutions

445

Shares Held

129M

Call Options Held

5.25M

Put Options Held

1.18M

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $6.25B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.

Account